M

Madrigal Pharmaceuticals
D

MDGL

442.03
USD
-3.24
(-0.73%)
مغلق
حجم التداول
16,842
الربح لكل سهم
-5
العائد الربحي
-
P/E
-34
حجم السوق
10,039,128,983
أصول ذات صلة المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.